Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study.

Hangyu ZhangZhou TongLulu LiuQihan FuXudong ZhuXiaomeng DaiXuanwen BaoWeijia FangYi ZhengPeng Zhao

Published in: Gastroenterology report (2023)

IROX had no significant survival benefit over irinotecan monotherapy in our study. However, IROX reduced the risk of disease progression by 60%, with acceptable toxicity.

Keyphrases

open label
phase ii study
phase ii
clinical trial
phase iii
locally advanced
study protocol
combination therapy
placebo controlled
rectal cancer
replacement therapy